autoimmune disease treatment
Scope
Date
~
-
Bio & Pharma
Samsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma
South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...
Jul 15, 2022 (Gmt+09:00)
-
Bio & Pharma
Korean biotech firms fold COVID-19 therapeutics development businesses
A string of South Korean pharmaceutical and biotech companies are waving the white flag when it comes to developing COVID-19 treatments. As the...
Jul 04, 2022 (Gmt+09:00)
-
Corporate investment
Samsung Eng. to invest in Vietnam for SE Asia water biz
Samsung Engineering Co. agreed to spend $41 million on Vietnam’s largest private water treatment company for the eco-friendly business in Sout...
Jun 30, 2022 (Gmt+09:00)
-
Healthcare
CHA Healthcare buys major Australian fertility center
South Korea’s medical center operator CHA Healthcare Co. said on Monday it has acquired the management rights of Fertility Specialists of West...
Jun 27, 2022 (Gmt+09:00)
-
Bio & Pharma
Pharma companies jump into $3 bn pet care market
South Korean pharmaceutical companies are jumping into the animal medicine and diagnostics market to target the rapidly growing pet care market, whi...
Jun 24, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...
Jun 14, 2022 (Gmt+09:00)
language -
Bio & Pharma
Medipost acquires Canada’s OmniaBio for CDMO business
Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract devel...
May 31, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem receives FDA nod for CUE-102 cancer treatment phase 1 trials
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., has received the US Food and Drug Administration’s approval for phase 1 cli...
May 13, 2022 (Gmt+09:00)
-
Bio & Pharma
HK inno.N receives sales permit for ulcer treatment in China
HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company an...
Apr 13, 2022 (Gmt+09:00)
-
Bio & Pharma
FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval
The US Food and Drug Administration has begun reviewing a medicine developed by South Korea’s Hanmi Pharmaceutical Co. for marketing authoriza...
Apr 13, 2022 (Gmt+09:00)
-
Mergers & Acquisitions
SK Ecoplant buys e-waste recycling firm for $1 bn
South Korea's SK Ecoplant Co. has acquired Singapore-based electronic waste (e-waste) disposal and recycling company TES Envirocorp Pte. Ltd for $1 ...
Feb 21, 2022 (Gmt+09:00)
language -
Korean biotech startup signs license deal with US firm
South Korea's biotech startup Novelty Nobility Inc. has signed a global license agreement for its antibody treatment candidate with a US biopharmace...
Feb 17, 2022 (Gmt+09:00)
-
IPOs
Hyundai Engineering drops IPO plan on stock market weakness
Hyundai Engineering Co., the plant engineering and construction unit of South Korea’s Hyundai Motor Group, dropped a listing plan to raise up ...
Jan 28, 2022 (Gmt+09:00)
-
Pharmaceuticals
ABL Bio in $1.06 bn deal with Sanofi for Parkinson's disease treatment
South Korea’s ABL Bio Inc. has signed a $1.06 billion contract to license out its technology for a Parkinson's disease treatment candidate t...
Jan 12, 2022 (Gmt+09:00)
-
Pharamaceuticals
SK Biopharm releases epilepsy treatment in UK
South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europ...
Dec 21, 2021 (Gmt+09:00)
-
Forbes taps MBK and Nexon founders as Asia's philanthropy heroes
Michael ByungJu Kim, the founder of South Korean investment firm MBK Partners, and Kim Jung-ju, founder of Nexon, the largest online gaming compan...
Dec 14, 2021 (Gmt+09:00)
-
COVID-19
Celltrion to export COVID-19 treatment to Europe in 2021
South Korea’s pharmaceutical giant Celltrion Inc. is set to export its COVID-19 treatment Regkirona to Europe by the end of this year as it se...
Nov 30, 2021 (Gmt+09:00)
language -
Pharmaceuticals
Samsung Biologics wins another Eli Lilly COVID treatment order
Samsung Biologics Co., a global contract development and manufacturing organization (CDMO), has stepped up its partnerships with global big pharmas ...
Nov 19, 2021 (Gmt+09:00)
-
Waste treatment
Hyundai Motor Group seeks to buy Korea waste treatment firm
Hyundai Engineering Co., Hyundai Motor Group’s construction arm, has joined the race to buy a South Korean garbage treatment company as the gr...
Nov 16, 2021 (Gmt+09:00)
-
COVID-19
Celltrion wins COVID-19 treatment approval from Europe
South Korea’s pharmaceutical giant Celltrion Inc. has won final approval for its COVID-19 treatment Regkirona from the European Commission, a ...
Nov 15, 2021 (Gmt+09:00)
language -
Pharmaceuticals
High-priced drugs add to pressure for Korea's healthcare reform
A number of new rare disease treatments, approved in South Korea over the past year, are still unaffordable for the public because of their price ta...
Sep 15, 2021 (Gmt+09:00)
-
Non-ferrous metals
Korea Zinc emerges winner despite sharp decline in treatment fees
Just like many other manufacturers around the world, 2020 was a turbulent year for Korea Zinc Co., the world’s largest lead and zinc smelter.T...
Sep 05, 2021 (Gmt+09:00)
language -
Covid-19 treatment
Brazil gives emergency use nod for Celltrion’s COVID-19 treatment
South Korean drugmaker Celltrion Inc. has added Brazil to the list of countries that have granted emergency use approval for its COVID-19 treatment ...
Aug 13, 2021 (Gmt+09:00)
language -
COVID-19
Celltrion to enter clinical trials of new COVID-19 treatment
South Korean biosimilar maker Celltrion Inc. will launch the first-phase clinical trials of its new COVID-19 treatment candidate next month, followi...
Aug 05, 2021 (Gmt+09:00)
language -
Pharmaceuticals
TiumBio acquires stake in SK Plasma to beef up R&D for rare diseases
South Korea-based biopharmaceutical company TiumBio is set to acquire 30 billion won ($26 million) worth of shares in SK Plasma, a blood product com...
Jul 28, 2021 (Gmt+09:00)
-
COVID-19
COVID treatment deals drive Samsung Bio’s record quarterly earnings
South Korea’s Samsung Biologics Co. posted its highest quarterly revenue and operating profit, thanks largely to a number of long-term manufac...
Jul 28, 2021 (Gmt+09:00)
-
Covid-19 treatment
Indonesia grants emergency use approval for Celltrion’s COVID-19 treatment
South Korean drugmaker Celltrion Inc. has received the Indonesian government’s permission for restricted use of its COVID-19 treatment Regkiro...
Jul 20, 2021 (Gmt+09:00)
-
Waste management
The power of rubbish: Korean firms make big money from garbage
There is money to be made in garbage. Such is the growing consensus among investors as well as waste treatment companies amid tighter environmental ...
Jul 15, 2021 (Gmt+09:00)
language -
COVID-19
Celltrion’s COVID-19 treatment reduces incidence of severity by 70%
Celltrion Inc. on July 13 said that its COVID-19 treatment Regkirona has proven effective in reducing the incidence of severe cases of the virus by ...
Jul 13, 2021 (Gmt+09:00)
language